Concepedia

Lauren Hargis

LH

4

Publications

1.9K

Citations

4

H-Index

2019

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Lauren Hargis is an author at Mirati Therapeutics (United States) specializing in medicine, t cell immunity, and drug discovery.

ORCID

Top concepts

Publications per year

2019–2022

4

Publications

4

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics · 2021 · 159 citations · Full text

Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

David M. Briere, Andrew Calinisan, Ruth Aranda et al. · Molecular Cancer Therapeutics · 2019 · 14 citations

, , +21

Rows per page

1–4 of 4